Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights GlobeNewswire - Fri Aug 14, 6:28AM CDT

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment...

HELP : 11.57 (-3.50%)
HELP.NE : 16.0000 (-3.67%)
Cybin Reports Earnings Today, Though the Market Seemed to Price Them In Three Months Early Barchart - Tue Aug 11, 4:04PM CDT

Barchart Research What to Expect from HELP Earnings HELP Generated August 11, 2026 Current Price $10.09 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 4.49% Cybin Reports Earnings Today,...

HELP : 11.57 (-3.50%)
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston GlobeNewswire - Mon Aug 10, 11:00AM CDT

NEW YORK and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to...

HELP : 11.57 (-3.50%)
HELP.NE : 16.0000 (-3.67%)
Helus Pharma Appoints Michael Halstead as Chief Executive Officer GlobeNewswire - Mon Aug 3, 6:40AM CDT

Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track...

HELP : 11.57 (-3.50%)
HELP.NE : 16.0000 (-3.67%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule PR Newswire - Tue Jul 21, 9:54AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program

HELP : 11.57 (-3.50%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates FinancialNewsMedia - Tue Jul 21, 7:30AM CDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 11.57 (-3.50%)
CMPS : 13.72 (+2.01%)
ATAI : 7.24 (-0.28%)
JNJ : 262.37 (+0.78%)
LLY : 1,183.16 (+0.25%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule FinancialNewsMedia - Tue Jul 21, 7:15AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program  Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data...

HELP : 11.57 (-3.50%)
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule GlobeNewswire - Tue Jul 21, 6:50AM CDT

Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability...

HELP : 11.57 (-3.50%)
HELP.NE : 16.0000 (-3.67%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity FinancialNewsMedia - Tue Jun 30, 8:00AM CDT

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 11.57 (-3.50%)
CMPS : 13.72 (+2.01%)
GHRS : 29.98 (+1.66%)
JNJ : 262.37 (+0.78%)
DFTX : 45.26 (+6.17%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity GlobeNewswire - Tue Jun 30, 8:00AM CDT

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 11.57 (-3.50%)
CMPS : 13.72 (+2.01%)
GHRS : 29.98 (+1.66%)
JNJ : 262.37 (+0.78%)
DFTX : 45.26 (+6.17%)

Barchart Exclusives

This Dividend Safety Stock Is Outperforming the S&P 500 in 2026 Barchart - Mon Aug 17, 6:30PM CDT
Owens Corning has risen 37% so far this year, owning solid second-quarter results that included healthy free cash flow and an EPS that beat estimates by nearly 27%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.